Biodesix Inc

+0.16 (+6.84%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)206.12M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$10.77 Million
Adjusted EPS-$0.28
See more estimates
10-Day MA$2.37
50-Day MA$1.85
200-Day MA$1.70
See more pivots

Biodesix Inc Stock, NASDAQ:BDSX

2970 Wilderness Place, Suite 100, Boulder, Colorado 80301
United States of America
Phone: +1.303.417.0500
Number of Employees: 218


Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The firm offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It also offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. The company was founded by David Brunel and Robert E. Cawthorn in 2005 and is headquartered in Boulder, CO.